Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition. Actemra is the first therapy approved by the FDA for the treatment of adult patients with GCA. This is the sixth FDA approval for Actemra since the medicine was launched in 2010.

“Today’s FDA decision means people living with giant cell arteritis will, for the first time, have an FDA-approved treatment option for this debilitating disease,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “With no new treatments in more than 50 years, this approval could be transformational for people with GCA and for their physicians.”

The approval is based on the positive outcome of the Phase III GiACTA study evaluating Actemra in patients with GCA. The results showed that Actemra, initially combined with a six-month steroid (glucocorticoid) regimen, more effectively sustained remission through 52 weeks (56 percent in the Actemra weekly group and 53.1 percent in the Actemra bi-weekly group) compared to placebo combined with a 26-week steroid taper (14 percent) and placebo combined with a 52-week steroid taper (17.6 percent).1

About the GiACTA study 
GiACTA (NCT01791153) is a Phase III, global, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Actemra as a novel treatment for GCA. It is the first successful clinical trial conducted in GCA and the first to use blinded, variable-dose, variable-duration steroid regimens. The multicenter study was conducted in 251 patients across 76 sites in 14 countries. The primary endpoint was evaluated at 52 weeks.

About Giant Cell Arteritis 
GCA, also known as temporal arteritis (TA), affects an estimated 228,000 people over the age of 50 in the U.S., and the disease is two to three times more likely to affect women than men.2,3 GCA is often difficult to diagnose because of the wide and variable spectrum of signs and symptoms. GCA can cause severe headaches, jaw pain and visual symptoms and if left untreated, can lead to blindness, aortic aneurysm or stroke.3 Treatment to date for people with GCA has been limited to high-dose steroids that play a role as an effective ‘emergency’ treatment option to prevent damage such as vision loss.3 Due to the variability of symptoms, complexity of the disease and disease complications, people with GCA are often seen by several physicians including rheumatologists, ophthalmologists and neurologists.

About Actemra 
Actemra is the first humanized interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), that did not provide enough relief. The extensive Actemra RA IV clinical development program included five Phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. The Actemra RA subcutaneous clinical development program included two Phase III clinical studies and enrolled more than 1,800 people with RA in 33 countries. In addition, Actemra is also used as an IV formulation for patients with active polyarticular juvenile idiopathic arthritis (PJIA) or systemic juvenile idiopathic arthritis (SJIA) two years of age and older. Actemra is not approved for subcutaneous use in people with PJIA or SJIA. It is not known if Actemra is safe and effective in children with PJIA or SJIA under two years of age or in children with conditions other than PJIA or SJIA.

Actemra is intended for use under the guidance of a healthcare practitioner.

 

About Genentech 
 
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

References

1 Stone JH, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

2 Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part II. Arthritis Rheum. 2008; 58: 26-35.

3 Bhat S, et al. Giant cell arteritis. Midlife and Beyond, GM. Rheumatology. February 2010; 071-079.

 

To view the full report including important safety information click here.

13 thoughts on “FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis”

  1. Wow, this piece of writing is pleasant, my sister is analyzing these things,
    so I am going to tell her.

  2. g says:

    Genuinely no matter if someone doesn’t know then its up to other users that they will assist, so here it happens.

  3. I have been browsing online more than 3 hours today, yet I never found any interesting article like
    yours. It is pretty worth enough for me. In my
    view, if all web owners and bloggers made good content as you did, the net will be
    a lot more useful than ever before.

  4. Excellent post. I was checking continuously
    this blog and I am inspired! Extremely helpful info specifically the remaining part
    🙂 I take care of such information a lot. I was looking for this particular
    information for a very long time. Thanks and good luck.

  5. Hello there! Do you use Twitter? I’d like to follow you if that would be okay.
    I’m absolutely enjoying your blog and look forward to new posts.

  6. I do not know whether it’s just me or if perhaps everybody else encountering problems with your site.
    It seems like some of the text within your content are running off the screen.
    Can someone else please provide feedback and let me know if
    this is happening to them as well? This might be a issue with my browser because I’ve had this happen previously.
    Thank you

  7. WOW just what I was searching for. Came here by searching
    for gamefly free trial

  8. Ahaa, its nice dialogue concerning this article here at this weblog, I have read all that, so at
    this time me also commenting at this place.

  9. An intriguing discussion is worth comment. I believe that you ought to publish more about this
    topic, it might not be a taboo matter but usually folks don’t discuss such subjects.
    To the next! Many thanks!!

  10. tinyurl.com says:

    Superb, what a webpage it is! This weblog gives useful information to us, keep it up.

  11. WOW just what I was looking for. Came here by searching for ps4 best games ever
    made 2019

  12. I was able to find good information from your blog articles.

  13. Wow, this article is fastidious, my sister is analyzing these things, so I am going
    to tell her.

Leave a Reply

Your email address will not be published.

X